Overview of Nasic kids

Quick Facts

Property	Description
Active ingredient	Xylometazoline hydrochloride, Dexpanthenol
Form	Aqueous Nasal Spray Solution
Pharmacological Class	Nasal Decongestant and Mucosal Healing Agent
Common Use	Symptomatic relief of nasal congestion and irritation during a cold
Target Group / Positioning	Specifically formulated for children aged 2 to 6 years

1. What Type of Medicine is Nasic kids? (Identity and Classification)

Nasic kids is a dual-action, synthetic combination medicine delivered as a topical nasal spray specifically manufactured for young children. It is classified as a combination drug because it features two distinct active pharmaceutical ingredients. The primary component, Xylometazoline hydrochloride, is a recognized nasal decongestant used for the relief of nasal congestion. This medicine is an aqueous solution applied locally into the nose for a fast, targeted effect, making its formulation appropriate for the pediatric patient group of 2 to 6 years.

2. What Active Ingredients Make Up the Formula? (Composition)

The formula combines Xylometazoline hydrochloride (INN) and Dexpanthenol (INN) to achieve its comprehensive relief. Xylometazoline hydrochloride is the nasal decongestant used for reducing swelling in the nasal passages. The second ingredient, Dexpanthenol, is an alcohol derivative of pantothenic acid (a provitamin) known for its wound healing and mucosal protective properties. The combination is designed so that the addition of Dexpanthenol can help protect the delicate nasal lining from the drying effects often associated with the use of decongestants.

3. Why Use a Dual-Action Nasal Spray? (General Purpose)

The general purpose of Nasic kids is to provide combined relief by simultaneously clearing nasal obstruction and supporting the recovery of the irritated nasal lining. This dual action provides a more complete therapeutic approach: the decongestant helps to open the blocked nose, while the mucosal protective agent helps to stabilize the moisture balance and promote the healing of the affected membrane. The combination of ingredients is intended to improve patient comfort and reduce irritation commonly experienced during the course of a cold. This dual approach is a differentiating factor from single-action saline or pure decongestant sprays.

Regulatory References

WHO Model Lists of Essential Medicines

What side effects are possible with Nasic kids?

The safety profile for the Xylometazoline/Dexpanthenol combination is based on official government regulatory documents, which categorize known adverse reactions by frequency and affected organ system.

Adverse Reaction Scope

Classification	Examples of Officially Documented Adverse Reactions
Common (ge 1/100 to < 1/10)	Stinging or burning sensation in the nose and throat, dry nasal mucous membranes, sneezing.
Rare (ge 1/10,000 to < 1/1,000)	Palpitations, tachycardia, hypertension (increased blood pressure), nausea.
Very Rare (< 1/10,000)	Restlessness, hallucinations (primarily in children), headache, convulsions, arrhythmia, fatigue.

Adverse effects are also categorized by System-Organ Class (SOC), including Respiratory, thoracic, and mediastinal disorders (local reactions), Cardiac disorders, Vascular disorders, Nervous system disorders, and Immune system disorders (hypersensitivity reactions like angioedema).

Safety Constraints and Considerations

The product is formally contraindicated in specific conditions defined in the official labeling due to safety concerns, including rhinitis sicca (dry inflammation of the nasal mucosa), angle-closure glaucoma, and a history of certain surgical interventions that exposed the dura mater.

Safety documents emphasize population-specific concerns, noting that the majority of severe adverse neurological events reported in young children, such as convulsions and CNS depression, occurred following overdose or high systemic absorption of the Xylometazoline component. Additionally, the label documents that rebound congestion (rhinitis medicamentosa) and mucosal atrophy are safety patterns associated with prolonged use or exceeding the recommended dosage. The risk of systemic effects, such as increased blood pressure, is noted to be amplified by concomitant use with certain medications, including monoamine oxidase inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Nasic kids nasal spray contains xylometazoline and dexpanthenol. Overdosing is primarily related to the effects of xylometazoline, a vasoconstrictor, especially in young children. Dexpanthenol is generally not associated with serious overdose symptoms.

Overdose with xylometazoline can cause effects related to both central nervous system depression and stimulation. Symptoms often develop within minutes to a few hours after excessive use or accidental ingestion and may include:

Central Nervous System Depression: Drowsiness, dizziness, lethargy, significant drop in body temperature (hypothermia), low blood pressure (hypotension), slow heartbeat (bradycardia), and even coma or respiratory depression.
Central Nervous System Stimulation: Restlessness, anxiety, agitation, high blood pressure (hypertension), fast heartbeat (tachycardia), hallucinations, or convulsions.

When to Seek Emergency Help

If you suspect an overdose or accidental ingestion of Nasic kids, it is crucial to seek emergency medical attention immediately. This is especially vital if the child exhibits any of the following severe symptoms:

Significant drowsiness or unresponsiveness.
Slow, shallow, or irregular breathing.
Very slow or very fast heartbeat.
Convulsions or seizures.
Loss of consciousness.

Always contact a local Poison Control Center or emergency medical services right away. Do not attempt to induce vomiting unless specifically instructed by a medical professional.

Therapeutic Uses of Nasic kids

What Nasic kids Treats: Main Uses and Benefits

The Xylometazoline and Dexpanthenol combination is commonly used for managing symptoms related to nasal congestion and irritation or superficial lesions of the nasal lining in children aged 2 to 6 years. The therapeutic aims for this combination are centered on reducing the symptoms related to nasal mucosa swelling and providing supportive care for irritated nasal tissue.

The medicine is relevant across domains where additional symptomatic support is needed, and is commonly used to help with acute rhinitis (the common cold), nasal obstruction symptoms in post-surgical contexts, and irritative states of the nasal mucosa.

Quick Fact: Symptom Management Context The product is relevant for easing symptoms related to both physiological strain from a blocked nose and the discomfort caused by irritated internal membranes.

This formulation is used when symptoms create noticeable interference with daily comfort, offering supportive relief that helps patients cope more steadily with symptom fluctuations. The medicine is applied in addressing symptoms that interfere with daily functioning, providing short-term symptomatic assistance to ease the physiological strain of obstructed breathing, and contributes to easing the overall symptom load associated with irritative states. It is considered relevant for managing nasal obstruction symptoms in specialized scenarios, such as when supportive symptom management is appropriate after nasal surgery.

Regulatory References

Irish Health Products Regulatory Authority (HPRA)

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nasic kids — Official Regulatory Information

This section outlines the official population eligibility and non-eligibility status for Nasic kids (Xylometazoline/Dexpanthenol 0.05% nasal spray), as strictly defined in governmental regulatory documents.

Category	Eligibility Status (Regulatory Wording)
Populations for whom use is allowed (as stated in label)	Children aged 2 to 6 years are indicated for this specific strength [Source 2.1].
Populations for whom use is not recommended	Pregnant women (Use is not recommended/should not be used) [Source 2.1]. Breastfeeding women (Use should be avoided/not recommended) [Source 2.1].
Populations for whom use is contraindicated	Children under 2 years of age [Source 1.1, 2.1]. Patients with Rhinitis Sicca (dry inflammation of nasal mucosa) [Source 2.1]. Patients with narrow-angle glaucoma [Source 2.1]. Patients with a history of transsphenoidal hypophysectomy or surgery exposing the dura mater [Source 2.2]. Patients currently using or having used MAOIs within the last two weeks [Source 2.2].
Age-related eligibility rules	Approved: Children 2 to 6 years. Prohibited: Children under 2 years (Contraindicated) [Source 2.1, 2.2]. Not Indicated (for this strength): Children over 6 years and adults [Source 2.1].
Condition-specific eligibility rules	Use must be with caution in patients with severe cardiovascular diseases (e.g., hypertension), diabetes mellitus, hyperthyroidism, or pheochromocytoma [Source 2.2, 2.4]. Use during chronic rhinitis must be done under medical supervision [Source 2.2].

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use this medicine by strictly setting the approved age range (2 to 6 years) and establishing non-negotiable prohibitions for specific pre-existing conditions and drug interactions (Contraindications), alongside mandating cautious use for individuals with specific systemic vulnerabilities (e.g., severe heart conditions) due to the systemic absorption of the decongestant component.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Nasic kids is primarily defined by the sympathomimetic effects of Xylometazoline hydrochloride, which can cause clinically significant pharmacodynamic interactions with certain classes of medicinal products.

Documented Interaction Restrictions

Classification	Interacting Agents	Official Constraint
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to the high risk of a potentiated pressor effect, leading to a hypertensive crisis. Xylometazoline must not be administered during MAOI use or for 14 days after stopping MAOI therapy.
Caution Required	Tricyclic and Tetracyclic Antidepressants	Concomitant use may increase blood pressure and is generally not recommended, based on documented sympathomimetic effects.
Additive Risk	Other Sympathomimetic Agents (in cold remedies)	Co-administration may result in additive effects on the cardiovascular system and the central nervous system.

Due to the nasal spray's local application and minimal systemic absorption, official regulatory labeling indicates that pharmacokinetic interactions involving metabolic enzymes or drug transporters (such as CYP enzymes or P-gp) are considered unlikely to be clinically relevant. The regulatory profile also notes that patients with long QT syndrome may be at an increased risk of serious ventricular arrhythmias when treated with Xylometazoline.

Mechanism of Action

Local Reduction of Swelling via alpha-Adrenergic Receptors

The pharmacodynamic action is initiated by Xylometazoline, which functions as an agonist of alpha-adrenergic receptors located on the smooth muscle of blood vessels in the nasal lining. This receptor activation triggers the sympathetic nervous system cascade, compelling the smooth muscle to contract (vasoconstriction). This core mechanism restricts localized blood flow and initiates the physiological change of decreased mucosal volume. The result is a reduction in tissue volume, which permits increased nasal passage diameter.

Supporting Epithelial Repair and Barrier Function

The second active component, Dexpanthenol, operates via metabolic and structural support. It penetrates the cells and is converted into pantothenic acid (Vitamin B5), a required precursor for Coenzyme A. Coenzyme A is essential for various metabolic pathways, including the synthesis of lipids necessary for cellular membrane maintenance. The action of Dexpanthenol operates parallel to the vasoconstrictive effect, supporting the cellular processes of re-epithelialization and contributing to the physical stability of the nasal mucosal barrier.

Dosage and Administration Information

Administration Guidelines: How to Use Nasic kids

Nasic kids is an aqueous nasal spray solution containing Xylometazoline hydrochloride and Dexpanthenol, intended for administration in the target pediatric group of 2 to 6 years.

Administration Scope	Instruction
Route of administration	Topical nasal use (Local application as a metered spray).
Dosing schedule	One spray into each nostril.
Age-group administration rules	Intended for use in children aged 2 to 6 years.
Maximum daily frequency	Applied up to 3 times per day, with the total not to exceed 3 applications per nostril daily.
Course duration	The medicine should not be used for longer than 7 consecutive days.

Procedural and Contextual Instructions

The administration of the spray is symptomatic rather than fixed-schedule and follows specific contextual requirements:

Preparation: The nose should be cleaned by blowing vigorously before application to ensure the solution makes effective contact with the nasal mucosa.
Technique: During application, the patient should lightly inhale through the nose while spraying.
Supervision: Use in the 2-to-6-year-old pediatric group must be supervised by an adult.
Timing: The last dose of the day is preferably applied before retiring to bed to support comfort during sleep.
Hygiene: Each spray bottle should be used by only one person to prevent the risk of infection transmission.

This protocol defines the approach to using the medicine, limiting its short-term use and involving adult oversight for the pediatric dosage schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nasic kids

Evidence for the Relief of Nasal Congestion in the Common Cold

Research for the Xylometazoline/Dexpanthenol combination primarily involves short-term, randomized controlled trials (RCTs) and active-controlled studies. These trials have typically been conducted on adult populations experiencing congestion due to the common cold. The studies were applied in studies examining patient-reported experiences by comparing the combination spray to Xylometazoline monotherapy. Outcomes were measured using patient-reported outcomes describing perceived discomfort, focusing mainly on the degree of nasal congestion and other symptoms related to inflammation.

The studies report patterns related to how symptoms changed in the observed populations over a few days, often up to a week. Findings describe patterns observed in the studies related to changes in nasal blockage within the short treatment period. Research also explored patient-reported outcomes describing perceived differences in physical discomfort, particularly irritation or dryness, when using the combination product compared to Xylometazoline monotherapy.

Research on Supportive Care for Irritated Nasal Mucosa

Research has also examined the combination in specialized research scenarios, particularly in adults who have undergone nasal operations and were experiencing irritated or damaged nasal linings. These controlled clinical studies were applied in studies examining patient-reported experiences and objective measures of mucosal integrity, such as the formation of crusts in the nasal passages. This evidence contributes to understanding the product’s evaluation in conditions involving periods of heightened symptoms related to local irritation.

Evidence Base for Children Aged 2 to 6 Years

Research in children aged 2 to 6 years relies less on dedicated, comparative efficacy trials and more on established knowledge of the individual components and age-appropriate dosing research. Studies monitored in this young age group were primarily concerned with determining the correct low-dose concentration and evaluating the local tolerability and systemic absorption of the ingredients.

Research in this age group generally relies on existing data and extrapolation from studies in older populations. Direct comparative evidence is lacking; findings were mixed regarding the comparative evidence for the combination against alternatives in this specific age group. Data for certain groups remain insufficient, highlighting the need for more dedicated, independent research in the young pediatric population.

Quality of Evidence and Key Research Limitations

Long-term outcomes are not fully established. The available research provides limited insight into extended-duration data or the potential for durability of response beyond the defined time intervals of the studies. Key limitations noted in the research landscape include the focus on adults for efficacy data, leading to the extrapolation of results to the low-dose children’s formulation. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Key Studies & References

Summary of Product Characteristics (SPC) for Septanazal for children (Regulatory basis for 2-6 years old)

Frequently Asked Questions (FAQ)

Common questions about Nasic kids (FAQ)

Q: What is meant by the term 'rebound effect' when discussing nasal sprays?

Regulatory documents describe a safety pattern called rebound congestion or rhinitis medicamentosa. This occurs when the nasal swelling returns or worsens after the decongestant effect wears off or if the product is used for too long. Official warnings note that prolonged use or exceeding the recommended frequency can lead to this chronic swelling and potential atrophy (shrinkage) of the nasal lining.

Q: Is it possible to become dependent on Nasic kids if used often?

Official safety warnings advise that long-term use or overdosing should be avoided. The primary risk noted is the development of rebound congestion and the potential for the nasal lining to atrophy (shrink), which can cause discomfort. Regulatory documents focus on these physical safety patterns and do not use the specific terms 'dependence' or 'addiction'.

Q: Can Nasic kids be used at the same time as cold medicine given by mouth?

Official information warns against using this medicine alongside other sympathomimetic agents. These are medicines, often found in oral cold remedies, that work similarly to the decongestant in Nasic kids. Combining them may result in additive effects on the central nervous system or the heart and blood pressure.

Q: Does using Nasic kids affect a child's sleep?

Official documents list central nervous system effects such as restlessness and insomnia (difficulty falling or staying asleep) as very rare side effects (affecting less than 1 in 10,000 people). The official administration protocol describes that the last dose of the day is preferably administered before retiring to bed to support comfort during sleep.

Q: Is Nasic kids safe to use if a child has a known heart condition?

Patients with severe cardiovascular diseases, such as hypertension (high blood pressure) or long QT syndrome, are subject to special warnings. Official product information indicates that use requires discussion with a doctor before starting. Rare side effects associated with the decongestant component include increased heart rate (tachycardia) and increased blood pressure (hypertension).

Q: Can Nasic kids be used for children who have chronic stuffy noses?

Official regulatory documents state that use for chronic rhinitis (a long-term stuffy nose) is indicated for use under medical observation. This is due to the potential risk of atrophy of the nasal mucosa, which is associated with prolonged use beyond the recommended duration.

Q: What is the typical time frame for symptoms to improve after starting Nasic kids?

The active ingredient Xylometazoline is a topical decongestant that is described as beginning its action to reduce swelling within minutes of administration. The medicine is dosed up to three times daily, suggesting the intended duration of relief for a single application is approximately 8 to 10 hours.

Q: Are there any warnings about using Nasic kids in combination with psychiatric medications?

Official documents describe specific interaction warnings. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs), including for 14 days after stopping them. Caution is also required for concomitant use with certain other psychiatric medicines, such as tricyclic and tetracyclic antidepressants, due to the risk of increased blood pressure.

Q: Does Nasic kids have a different formula for children?

Yes, Nasic kids is a specific formulation. The official label describes it as containing a lower concentration of the active ingredients (Xylometazoline and Dexpanthenol) that is specifically intended and approved for use in children aged 2 to 6 years.

Q: How quickly does Nasic kids typically start working?

The active ingredient Xylometazoline works by causing local blood vessels in the nose to constrict (tighten). Official information indicates that this decongestive effect typically begins within minutes of administering the spray.

Q: How long does the effect of Nasic kids usually last?

The recommended maximum dosing interval is up to every 8 to 10 hours. This period is consistent with the intended duration of the decongestant's action for a single dose.

Q: Is Nasic kids suitable for children with certain allergies?

Official product information indicates that the medicine is used for the symptomatic treatment of nasal congestion in conditions such as the common cold and rhinitis vasomotorica (episodic runny nose). Some Xylometazoline-containing products are also used for symptoms related to allergic rhinitis or hay fever.

Q: Is there a version of Nasic kids without a preservative?

The official list of excipients (inactive ingredients) for the spray solution includes benzalkonium chloride solution. This substance is commonly used as a preservative in medicines.

Q: Does Nasic kids contain steroids?

The active ingredients listed in the official formula are Xylometazoline hydrochloride (a decongestant) and Dexpanthenol (a mucosal healing agent). Steroid compounds are not listed as active components in the formula.

Q: What happens if I forget to use a dose of Nasic kids?

Official instructions specify that a person is not to take a double dose to make up for the one that was forgotten. The protocol states that administration should continue with the next scheduled dose.

Q: Can Nasic kids be used for a stuffy nose caused by seasonal allergies?

Q: What are the ingredients listed as inactive in Nasic kids?

The inactive ingredients (excipients) listed in the formula include purified water, potassium dihydrogen phosphate, disodium phosphate dodecahydrate, and the preservative benzalkonium chloride solution.

Q: Does Nasic kids address sinus pressure?

The medicine is indicated for the temporary symptomatic treatment of nasal congestion due to sinusitis or rhinitis. Reducing the swelling associated with congestion is the mechanism for addressing this symptom.

Q: Does Nasic kids contain alcohol?

Official regulatory documents do not list ethanol (alcohol) as an excipient (inactive ingredient) in the formula.

Q: Is Nasic kids associated with nosebleeds in children?

Official safety documents list nosebleeds as an uncommon side effect associated with Xylometazoline-containing nasal sprays, meaning they may affect up to 1 in 100 people.

How should Nasic kids be stored and disposed of?

Storage and Disposal of Nasic Kids Nasal Spray

This section outlines the officially documented storage and disposal requirements for the medicine, ensuring product stability and safe handling.

Storage Conditions

Requirement	Description
Child Safety	Keep this medicine out of the sight and reach of children.
Unopened Product	No special storage conditions are required.
Opened Product	Do not store above 25°C (77°F) after first opening.
Shelf Life After Opening	Use within 6 months (fixed head) or 12 weeks (screw-on head).
Expiry	Do not use after the expiry date printed on the label and carton.

Disposal Instructions

Unused or expired Nasic Kids must not be disposed of in waste water or household waste. For proper environmental disposal, ask a pharmacist how to discard the medicine.

Nasic kids